Mizuho Downplays Merck (MRK) KEYTRUDA Competition in 1L NSCLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus
October 29, 2019 6:47 AM EDTMerck (NYSE: MRK) reported Q3 EPS of $1.51, $0.27 better than the analyst estimate of $1.24. Revenue for the quarter came in at $12.4 billion versus the consensus estimate of $11.63 billion.
Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health VaccinesKEYTRUDA Sales Grew 62% to $3.1 Billion;... MoreMerck (MRK) Trades Lower Following AstraZeneca (AZN) Imfinzi Results, Down 0.70%
October 28, 2019 11:39 AM EDTMerck (NYSE: MRK) Trades Lower Following AstraZeneca (NYSE: AZN) Imfinzi Results, Down 0.70%
... More